HHS HARTE HANKS INC Insider Trading

10% Owner Rosenbach buys 8,400 shares of HHS at $5.36; stock down -48.2% from 52-week high, company unprofitable

Rosenbach, a 10% owner of Harte Hanks, purchased 8,400 shares at $5.36 on 2023-07-12, increasing his holdings from 753,333 shares to 761,733 shares. The purchase occurs within a challenging context: the company reported net income of $-392,000.00 in the latest quarter, operates at a -3.3% annual revenue decline, and the stock has fallen -48.2% from its 52-week high and -9.0% in the preceding 30 days. With a market cap of $33,508,156.50 and current price of $4.55, the transaction represents insider capital deployment in a deteriorating financial environment where profitability has eroded. Investors should focus on whether this reflects confidence in a turnaround or structural business headwinds that insider liquidity cannot reverse.

Director Radoff Bradley Louis bought 17,225 shares at blended average $5.83, expanding stake 4.6% to 391,399 shares (12/5/24).

Radoff Bradley Louis, a Director of Harte Hanks Inc (HHS), executed 19 separate purchases totaling 17,225 shares for $100,389.22 on 2024-12-05, acquiring shares at prices ranging from $5.75 to $5.89 with a blended average of $5.83. His holdings increased from 374,174 shares to 391,399 shares post-transaction. The transaction occurred in a context of material weakness: the stock has declined 17.1% over the past 30 days and 19.1% over 90 days, trading 32.5% below its 52-week high of $8.79. Harte Hanks is operationally challenged—annual revenue declined 7.2% year-over-year, the company was unprofitable over its most recent full fiscal year, and the market cap stands at $43.2M. The multi-tranche execution pattern (19 buys across a narrow price band of $5.75–$5.89 on a single day) is notable given the company's small market cap and weak fundamentals, though outcomes from this director's five prior purchases at HHS on 2024-12-04 remain unmeasurable.

HHS Director Radoff bought 42,775 shares for $241,551.15 in 22 transactions on 2024-12-04

Radoff Bradley Louis, a director at Harte Hanks Inc, executed 22 separate open-market purchases on 2024-12-04 totaling 42,775 shares for $241,551.15 at a blended average price of $5.65, increasing his holdings from 331,399 to 374,174 shares (+12.9%). The transaction occurred as the stock trades at $5.89, down 33.0% from its 52-week high of $8.79 and has declined 15.5% over the prior 30 days. The company faces structural headwinds: revenue of $47,630,000 annually is contracting at 7.2% year-over-year, and the company reported negative full-year net income, leaving a net income figure of only $142,000 for the latest quarter. The fragmented purchase pattern across multiple price points ($5.50–$5.70) suggests systematic accumulation rather than opportunistic timing. Investors should weigh this substantial insider accumulation against the company's deteriorating profitability and declining top-line growth trajectory.

CFO bought 850 shares at $5.80 on 2024-11-25; stock -18.9% (30d), HHS down -7.2% annually, unprofitable.

CFO Garrison David A purchased 850 shares at $5.80 on 2024-11-25, expanding his holdings to 13,129 shares (+6.9% vs pre-transaction). This is the third Form 4 filing from him in seven days; he initiated five open-market purchases at HHS on 2024-11-18, followed by this transaction one week later. The timing occurs amid material headwinds: HHS trades 32.8% below its 52-week high of $8.79, has declined 18.9% over the past 30 days, and faces structural challenges including annual revenue contraction of -7.2% and negative full-year net income, with latest quarterly net income of $142.0K on revenue of $47.6M. The CFO's cross-ticker track record shows a 50.00% win rate on prior buys (90d returns), though no same-ticker outcomes are yet measurable given the recency of his five November 18 purchases. The rapid cadence and scale of accumulation merit observation given the company's profitability and growth headwinds.

CFO Garrison buys 3,904 shares for $25,637.96 across 7 transactions on 2024-11-18; holdings up 46.6%.

David A. Garrison, Chief Financial Officer of Harte Hanks Inc., executed 7 separate purchases totaling 3,904 shares for $25,637.96 on November 18, 2024, raising his holdings from 8,375 to 12,279 shares—a 46.6% increase in position size. The purchases occurred at prices ranging from $6.40 to $6.65 (blended average $6.57), while the stock currently trades at $6.36, down 27.6% from its 52-week high and 12.6% lower over the past 30 days. Garrison's prior open-market purchases at this same ticker (4 trades since May) showed mixed timing outcomes: 3 of the 4 achieved positive 30-day returns (ranging 4.4% to 8.4%), but only 2 of 4 delivered positive 90-day returns, indicating inconsistent longer-term conviction. The company's fundamentals remain stressed—annual revenue declined 7.2%, full-year net income was negative, and the latest quarterly net income was only $142,000 on $47.6M revenue—leaving unclear whether this accumulation reflects bottom-fishing or a strategic response to operational challenges.

Director Radoff bought 73,900 shares over 3 days at blended avg $7.22; holdings jump 30.6% to 315.2K shares

Radoff Bradley Louis, a Director at Harte Hanks, executed 3 separate purchases totaling 73,900 shares for $533,859.21 between August 13–15, 2024, at an average price of $7.22. His post-transaction holdings increased 30.6% to 315.2K shares. This substantial purchase occurs as the stock trades 16.4% below its 52-week high and within his prior same-ticker history where 2 of 2 prior buys at HHS showed positive 90-day returns, establishing a pattern of well-timed entry points at this ticker. However, the company reported a net loss of $27.8M on $45.0M revenue in the latest quarter, with annual revenue declining 7.2%, creating meaningful fundamental headwinds that constrain the signal's weight. The cluster pattern of 2 other insiders also buying within the past 14 days lends incremental credibility to the purchase, but the company's unprofitability and recent equity market underperformance suggest this transaction warrants closer attention to the underlying business trajectory.

CFO Garrison buys 4,250 shares of HHS at $7.03 avg, doubling stake to 8,375; stock down 22.4% from 52-week high.

Chief Financial Officer David A Garrison purchased 4,250 shares across 3 separate transactions on 2024-08-12 at a blended average price of $7.03, increasing his holdings by 103.0% from 4,125 to 8,375 shares. The acquisition occurred as HHS stock trades 22.4% below its 52-week high and down 18.9% over 30 days. Contextually, the company reported a net loss of $-27,834,000 in its latest quarter, annual revenue declined 7.2% year-over-year, and market capitalization stands at $49,710,864.06. The timing warrants attention: Garrison's single prior buy at HHS (2024-05-13) showed a 90-day return of -0.4%, establishing a pattern of open-market purchases in a structurally challenged operating environment.

CEO Kirk Davis bought 7,143 shares at $7.00 blended price (2 transactions totaling $49,998.56), raising holdings 32.0% despite stock down 22.4% from 52-week high and company unprofitable.

Davis Kirk A, CEO of Harte Hanks, purchased 7,143 shares (7.1K shares) for $49,998.56 ($50.0K) across 2 transactions on 2024-08-12 at a blended average price of $7.00, boosting his holdings by 32.0% to 29,474 shares (29.5K shares). The timing is notable given price context: the current stock price of $6.82 sits 22.4% below its 52-week high of $8.79, and the company is unprofitable (net income $-27.8M on latest quarterly revenue of $45.0M, with annual revenue declining 7.2%). His prior 5 purchases at HHS all occurred in May 2024, each delivering 90-day returns between 1.0% and 2.4%, suggesting a pattern of disciplined timing at this ticker; his cross-ticker track record is stronger (18 prior buys with 100.00% 90d win rate and avg 90d return +13.1%). This purchase of $50.0K represents substantial personal capital commitment from the chief executive, though the gap between his $7.00 transaction price and current $6.82 price (a decline already in the short term) signals the sale of a depressed asset into an uncertain environment for a struggling company.